Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
67%(4 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_2
2
22%
Ph phase_3
3
33%
Ph phase_1
1
11%

Phase Distribution

1

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(6)
Terminated(1)
Other(1)

Detailed Status

Completed6
Not yet recruiting1
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 22 (33.3%)
Phase 33 (50.0%)

Trials by Status

not_yet_recruiting111%
completed667%
unknown111%
terminated111%

Recent Activity

0 active trials
Showing 5 of 9
terminatedphase_2

Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP

NCT04720261
completedphase_3

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

NCT05468320
not_yet_recruiting

Impact of Acute ITTP Therapies on Long Term Neurologic and Cognitive Outcomes in ITTP Survivors

NCT06358703
completedphase_3

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

NCT02553317
completedphase_2

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

NCT01151423
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04720261Phase 2

Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP

Terminated
NCT05468320Phase 3

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

Completed
NCT06358703

Impact of Acute ITTP Therapies on Long Term Neurologic and Cognitive Outcomes in ITTP Survivors

Not Yet Recruiting
NCT02553317Phase 3

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

Completed
NCT01151423Phase 2

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Completed
NCT05785468

A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)

Unknown
NCT05263193

Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic Purpura (iTTP)

Completed
NCT02878603Phase 3

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

Completed
NCT02189733Phase 1

Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9